Mode
Text Size
Log in / Sign up
Phase 4 Completed N=24 Randomized Quadruple-blind Treatment

Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses

Source: ClinicalTrials.gov NCT02662023 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Sensory Deficit (Cold Roller), Mid-axillary Line — 9.2; 9.3 cm
◆ Published Evidence
Emerging
19citations · ~2 / year
Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method-Automatic Repeated Bolus Versus Continuous Basal Infusion-Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers.
Anesthesia and analgesia · 2017 · Open access · High-confidence link

Summary

Single-injection transversus abdominis plane (TAP) blocks have been used to treat postoperative pain, and are become very popular within the United States because of their high analgesic potency and relative ease of placement. Unfortunately, the longest local anesthetic available lasts only 8-12 hours. Continuous TAP blocks-also termed "perineural infusion"-involve bathing the multiple nerves of the abdominal wall in local anesthetic using a percutaneously-inserted perineural catheter inserted just anterior (ventral) and cephalad to the anterior superior iliac spine. For most catheter locations, an infusion is preferred to a single-injection nerve block because the duration of analgesia may be extended to better match the duration of surgical pain. But, unlike brachial plexus, femoral, and sciatic nerve perineural infusion, a continuous basal infusion of local anesthetic does not provide adequate analgesia for TAP catheters. This may be due to the fact that the TAP is a relatively tight space, so it might require a bolus of fluid to adequately spread the perineural local anesthetic to the multiple required nerves (as evidence of this, single-injection TAP blocks are very effective, although with a limited duration). The result is that while single-injection TAP blocks are widely used, TAP catheters have not been adopted. This scenario leaves surgical pain untreated following the resolution of the single-injection TAP block. The recent development of an infusion pump that can automatically deliver repeated bolus doses may allow the spread of local anesthetic to the multiple sensory nerves necessary to provide adequate analgesia, with a duration that better matches postoperative requirements. The investigators therefore propose a randomized, double-masked, controlled trial to determine if delivering local anesthetic as a repeated bolus dose results in improved local anesthetic spread/effects compared with a continuous basal infusion for TAP catheters.

Linked Publications

  • Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method-Automatic Repeated Bolus Versus Continuous Basal Infusion-Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers.
    Anesthesia and analgesia · 2017 · 19 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Sensory Deficit (Cold Roller), Mid-axillary Line
0; 0; 8.0; 2.9; 8.6; 7.8
SECONDARY
Sensory Deficit (Cold Roller), Mid-axillary Line
0; 0; 8.0; 2.9; 8.6; 7.8
SECONDARY
Sensory Deficit (Cold Roller), Transverse Horizontal Line
0; 0; 11.8; 7.7; 14.0; 14.3
SECONDARY
Sensory Deficit (Von Frey Hairs), Transverse Horizontal Line
0; 0; 7.6; 6.0; 10.7; 12.2
SECONDARY
Sensory Deficit (Von Frey Hairs), Mid-axillary Line
0; 0; 7.4; 3.0; 7.4; 6.9

Eligibility Criteria

Inclusion Criteria

  • healthy volunteers weighing more than 45 kg;
  • must be willing to have bilateral transverses abdominis plane nerve block catheters be placed with subsequent ropivacaine administration and sensory testing for 6 hours

Exclusion Criteria

  • BMI greater than 40 (BMI=weight in kg/ [height in meters];
  • regular opioid use within the previous 2 months;
  • previous participation within the same study;
  • allergy to study medications;
  • known renal insufficiency (creatinine > 1.5 mg/dL);
  • pregnancy;
  • incarceration; and
  • any known neuro-muscular deficit of either abdominal wall.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02662023) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search